...
首页> 外文期刊>Journal of hypertension >Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment.
【24h】

Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment.

机译:性别和年龄对通过降压治疗和乙酰水杨酸预防心血管疾病的影响。 HOT研究。高血压最佳治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: We have assessed the influence of gender and age on the main outcome results of the Hypertension Optimal Treatment (HOT) study. DESIGN AND INTERVENTIONS: The aims of the HOT study were to study the relationship between three levels of target office diastolic blood pressure (BP) (< or = 90, < or = 85 or < or = 80 mmHg) and cardiovascular (CV) events in hypertensive patients, and to examine the effects of 75 mg acetylsalicylic acid (ASA) daily versus placebo. SETTING: Outpatient clinical trial in 26 countries. PATIENTS: A total of 18790 patients (mean age 61.5 years, range 50-80) were randomized and followed for an average of 3.8 years until 71051 patient-years and 683 events had occurred. MAIN OUTCOME MEASURES: CV death, myocardial infarction (MI) and stroke. RESULTS: There were significantly fewer MIs in those in the lower diastolic BP target groups (3.0 versus 1.2 and 1.7 MIs/1000 patient-years, P for trend = 0.034) in women (n = 8883), whereas the similar but smaller trend (4.1 versus 4.1 and 3.4 MIs/1000 patient-years) was not statistically significant in men nor in the subgroup analysis of younger and older subjects. The effect of ASA on preventing MI was not influenced by age < 65 years (P= 0.02) or age > or = 65 years (P = 0.04) but was influenced by gender (P = 0.38 in women and P = 0.001 in men, lowered by 42% corresponding to a reduction from 5.0 to 2.9 MIs/1000 patient-years). CONCLUSIONS: The data of this HOT study sub-analysis suggest somewhat differentiated optimal gender- and age-dependent effects of anti-hypertensive and anti-platelet therapies; lowering of diastolic BP to about 80 mmHg in hypertensive women and, in addition, the administration of 75 mg of ASA to well-treated hypertensive men appear to effectively reduce the most common cardiovascular complication, i.e. myocardial infarction, in patients with essential hypertension.
机译:目的:我们评估了性别和年龄对高血压最佳治疗(HOT)研究主要结果的影响。设计与干预:HOT研究的目的是研究三个目标办公室舒张压(BP)(<或= 90,<或= 85或<或= 80 mmHg)与心血管(CV)事件之间的关系在高血压患者中,以及每天检查75毫克乙酰水杨酸(ASA)与安慰剂的比较。地点:26个国家的门诊临床试验。患者:总共18790例患者(平均年龄61.5岁,范围50-80岁)被随机分组​​,平均随访3.8年,直到71051例患者年和683起事件发生。主要观察指标:心血管死亡,心肌梗塞(MI)和中风。结果:女性(n = 8883)在舒张压较低的BP目标人群中,MIs明显较少(3.0 vs 1.2和1.7 MIs / 1000患者-年,P = 0.034),而趋势相似但较小(在男性中以及在年轻和老年受试者的亚组分析中,4.1 vs 4.1和3.4 MIs / 1000患者-年均无统计学意义。 ASA预防MI的效果不受年龄<65岁(P = 0.02)或年龄>或= 65岁(P = 0.04)的影响,但受到性别的影响(女性P = 0.38,男性P = 0.001,降低了42%,对应于每1000个患者年从5.0降到2.9 MIs。结论:该HOT研究子分析的数据表明抗高血压和抗血小板治疗的性别和年龄依赖性最佳效果有所不同。将高血压女性的舒张压降低至约80 mmHg,此外,对治疗良好的高血压男性给予75 mg ASA似乎可以有效减少患有原发性高血压的患者最常见的心血管并发症,即心肌梗塞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号